ACEA Biosciences announced today that it has signed a definitive agreement to join Agilent Technologies, Inc. (NYSE: A).
ACEA Biosciences is a company known for developing highly innovative products, which are used in academia, as well as the biotech and pharmaceutical industries. In recent years, the ACEA xCELLigence® RTCA technology has blazed a trail in immuno-oncology, pre-clinical drug discovery and development, as well as in basic academic research. The technology is complemented by the introduction in recent years of the NovoCyte® and NovoCyte Quanteon™ portfolio of high performance bench top flow cytometry systems.
Both ACEA and Agilent have a great reputation for scientific and technical innovation and for building systems and products of exceptional quality. As part of Agilent, ACEA will be able to leverage an unmatched global infrastructure of service and support, as well as a powerful global marketing and sales engine. Complementary engineering and scientific expertise from both companies should also provide a rich pipeline of novel systems and products well into the future.
“The analytical instruments, systems, and software developed by ACEA, dovetail perfectly with the strategic vision and mission of Agilent Technologies,” stated Xiao Xu, Chief Executive Officer of ACEA. “Agilent also has a number of complementary technologies, used in immuno-oncology and drug discovery, which should provide tremendous synergies.”
“ACEA represents a unique opportunity for Agilent to expand its team and broaden its portfolio with highly complementary technology, increasing the relevance and impact we can have with our customers in the cell analysis space” said Todd Christian, Vice President & General Manager of Agilent’s Cell Analysis Division. “We share the same passion around the need for and innovation of live-cell, kinetic, and label free approaches to cell analysis extending beyond traditional end-point measurements. Together, we will be able to offer a more comprehensive and compelling product portfolio to our collective customers.”
“Agilent and ACEA are aligned with a common mission to provide innovative high-performance solutions that help our customers advance scientific discovery and improve healthcare,” said Xiaobo Wang, President and Chief Technology Officer (CTO) of ACEA. “We are excited for the opportunities that this unique combination will create for both our employees and our customers.”
Agilent Technologies Inc. (NYSE: A) is headquartered in Santa Clara and is a global leader in life sciences, diagnostics, and applied chemical markets.
About xCELLigence® Real Time Cell Analysis (RTCA) Instruments
The xCELLigence® RTCA instruments use noninvasive biosensors to monitor and quantify cell proliferation, cell health, morphology changes, and attachment quality in a label-free, real-time manner. The xCELLigence RTCA instruments are being used in the academia, pharmaceutical, and biotech industries for applications ranging from cancer immunotherapy, cardiotoxicity, and drug discovery. To date, xCELLigence has been used in more than 1,400 publications, which can be viewed in a searchable library.
About NovoCyte® Flow Cytometers
The NovoCyte® and Novocyte Quanteon™ are high performance benchtop flow cytometers that are accessible to all levels of users. With one to three different laser options and a highly customizable optical platform, the NovoCyte® can be configured for diverse applications and is readily upgradeable over time. The NovoCyte Quanteon™ flow cytometer builds upon its wildly successful predecessor, the NovoCyte™, and provides an expanded set of capabilities that easily accommodate the large, multi-color panels found in today’s highly progressive flow cytometry laboratories. Scientists now have the flexibility to choose from 25 fluorescent channels utilizing four lasers (405, 488, 561, and 637nm) with 25 independent silicon photomultiplier (SiPM) detectors.
About ACEA Biosciences
Founded in 2002, ACEA Biosciences is a pioneer in the development and commercialization of high performance, cutting edge cell analysis platforms for life science research. ACEA’s xCELLigence impedance-based, label-free, real-time cell analysis instruments and NovoCyte® flow cytometers are used in pre-clinical drug discovery and development, toxicology, safety pharmacology, and basic academic research. More than 2,300 instruments have been placed globally.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics, and applied chemical markets. With more than 50 years of insight and innovation, Agilent instruments, software, services, solutions, and people provide trusted answers to its customers’ most challenging questions. The company generated revenues of $4.47 billion in fiscal 2017 and employs 14,200 people worldwide. Information about Agilent is available at www.agilent.com.
Follow on Linked In, Twitter, and Facebook
For further information please contact:
ACEA Biosciences, Inc.
J. Michael Honeysett, MBA
Vice President of Global Commercialization